PDF(Pubmed)
Abstract：
The outcome of multiple myeloma (MM) has significantly improved in the last few decades due to several factors such as new biological discoveries allowing to better stratify disease risk, development of more effective therapies and better management of side effects related to them. However, handling all these aspects requires an interdisciplinary approach involving multiple knowledge and collaboration of different specialists. The hematologist, faced with a patient with MM, must not only choose a treatment according to patient and disease characteristics but must also know when therapy needs to be started and how to monitor it during and after treatment. Moreover, he must deal not only with organ issues related to MM such as bone disease, renal failure or neurological disease but also with adverse events, often very serious, related to novel therapies, particularly new generation immunotherapies such as CAR T cell therapy and bispecific antibodies. In this review, we provide an overview on the newer MM diagnostic and monitoring strategies and on the main side effects of MM therapies, focusing on adverse events occurring during treatment with CAR T cells and bispecific antibodies.
摘要：
在过去的几十年中，由于一些因素，例如新的生物学发现，可以更好地对疾病风险进行分层，多发性骨髓瘤（MM）的预后得到了显着改善。开发更有效的治疗方法，并更好地管理与之相关的副作用。然而,处理所有这些方面都需要跨学科的方法，涉及多种知识和不同专家的合作。那个血液学家,面对一位MM患者，不仅必须根据患者和疾病的特点选择治疗方法，还必须知道何时需要开始治疗，以及如何在治疗期间和之后进行监测。此外，他不仅要处理与MM有关的器官问题，例如骨骼疾病，肾功能衰竭或神经系统疾病，但也有不良事件，往往很严重,与新疗法有关，特别是新一代免疫疗法，如CAR-T细胞疗法和双特异性抗体。在这次审查中,我们概述了较新的MM诊断和监测策略以及MM疗法的主要副作用，重点关注CART细胞和双特异性抗体治疗期间发生的不良事件。
